|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Delgado TC, Barbier-Torres L,
Zubiete-Franco I, Lopitz-Otsoa F, Varela-Rey M, Fernández-Ramos D
and Martínez-Chantar ML: Neddylation, a novel paradigm in liver
cancer. Transl Gastroenterol Hepatol. 3:372018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gerbes A, Zoulim F, Tilg H, Dufour JF,
Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten
TF, et al: Gut roundtable meeting paper: Selected recent advances
in hepatocellular carcinoma. Gut. 67:380–388. 2018. View Article : Google Scholar :
|
|
4
|
Forner A, Gilabert M, Bruix J and Raoul
JL: Treatment of intermediate-stage hepatocellular carcinoma. Nat
Rev Clin Oncol. 11:525–535. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruix J, Han KH, Gores G, Llovet JM and
Mazzaferro V: Liver cancer: Approaching a personalized care. J
Hepatol. 62(1 Suppl): S144–S156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al:
Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: A
randomised controlled trial. Lancet. 359:1734–1739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lepage C, Bossard N, Dejardin O,
Carmona-Garcia MC, Manfredi S and Faivre J; GRELL EUROCARE-5
Working Group: Trends in net survival from rectal cancer in six
European Latin countries: Results from the SUDCAN population-based
study. Eur J Cancer Prev. 26:S48–S55. 2017. View Article : Google Scholar
|
|
8
|
Nault JC, Mallet M, Pilati C, Calderaro J,
Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C and
Zucman-Rossi J: High frequency of telomerase reverse-transcriptase
promoter somatic mutations in hepatocellular carcinoma and
preneoplastic lesions. Nat Commun. 4:22182013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dhanasekaran R, Bandoh S and Roberts LR:
Molecular pathogenesis of hepatocellular carcinoma and impact of
therapeutic advances. F1000. Res. 5:F10002016.
|
|
10
|
Hussain SP, Schwank J, Staib F, Wang XW
and Harris CC: TP53 mutations and hepatocellular carcinoma:
Insights into the etiology and pathogenesis of liver cancer.
Oncogene. 26:2166–2176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bromberg JF: Activation of STAT proteins
and growth control. Bioessays. 23:161–169. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kisseleva T, Bhattacharya S, Braunstein J
and Schindler CW: Signaling through the JAK/STAT pathway, recent
advances and future challenges. Gene. 285:1–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wormald S and Hilton DJ: Inhibitors of
cytokine signal transduction. J Biol Chem. 279:821–824. 2004.
View Article : Google Scholar
|
|
14
|
Krebs DL and Hilton DJ: SOCS proteins:
Negative regulators of cytokine signaling. Stem Cells. 19:378–387.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Larsen L and Röpke C: Suppressors of
cytokine signalling: SOCS. APMIS. 110:833–844. 2002. View Article : Google Scholar
|
|
16
|
Poussin K, Pilati C, Couchy G, Calderaro
J, Bioulac-Sage P, Bacq Y, Paradis V, Leteurtre E, Sturm N, Ramos
J, et al: Biochemical and functional analyses of gp130 mutants
unveil JAK1 as a novel therapeutic target in human inflammatory
hepa-tocellular adenoma. Oncoimmunology. 2:e270902013. View Article : Google Scholar
|
|
17
|
Kang FB, Wang L, Jia HC, Li D, Li HJ,
Zhang YG and Sun DX: B7-H3 promotes aggression and invasion of
hepatocellular carcinoma by targeting epithelial-to-mesenchymal
transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int.
15:452015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ji Y, Wang Z, Li Z, Li K, Le X and Zhang
T: Angiotensin II induces angiogenic factors production partly via
AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells. Cell
Physiol Biochem. 29:863–874. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshikawa H, Matsubara K, Qian GS, Jackson
P, Groopman JD, Manning JE, Harris CC and Herman JG: SOCS-1, a
negative regulator of the JAK/STAT pathway, is silenced by
methylation in human hepatocellular carcinoma and shows
growth-suppression activity. Nat Genet. 28:29–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Roessler S, Jia HL, Budhu A, Forgues M, Ye
QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients. Cancer
Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roessler S, Long EL, Budhu A, Chen Y, Zhao
X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, et al: Integrative
genomic identification of genes on 8p associated with
hepatocellular carcinoma progression and patient survival.
Gastroenterology. 142:957–966.e12. 2012. View Article : Google Scholar :
|
|
23
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxida-tive phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lossos IS, Czerwinski DK, Alizadeh AA,
Wechser MA, Tibshirani R, Botstein D and Levy R: Prediction of
survival in diffuse large-B-cell lymphoma based on the expression
of six genes. N Engl J Med. 350:1828–1837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alizadeh AA, Gentles AJ, Alencar AJ, Liu
CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH,
et al: Prediction of survival in diffuse large B-cell lymphoma
based on the expression of 2 genes reflecting tumor and
microenvironment. Blood. 118:1350–1358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Huang K, Zeng X, Liu Z, Liao X,
Yang C, Yu T, Han C, Zhu G, Qin W and Peng T: Diagnostic and
prognostic value of mRNA expression of phospholipase C β family
genes in hepatitis B virusassociated hepatocellular carcinoma.
Oncol Rep. 41:2855–2875. 2019.PubMed/NCBI
|
|
29
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Montojo J, Zuberi K, Rodriguez H, Kazi F,
Wright G, Donaldson SL, Morris Q and Bader GD: GeneMANIA Cytoscape
plugin: Fast gene function predictions on the desktop.
Bioinformatics. 26:2927–2928. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maere S, Heymans K and Kuiper M: BiNGO: A
Cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar
|
|
33
|
Cai B, Cai JP, Luo YL, Chen C and Zhang S:
The specific roles of JAK/STAT signaling pathway in sepsis.
Inflammation. 38:1599–1608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu HP, Wu CL, Chen CK, Chung K, Tseng JC,
Liu YC and Chuang DY: The interleukin-4 expression in patients with
severe sepsis. J Crit Care. 23:519–524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Steinhauser ML, Hogaboam CM, Lukacs NW,
Strieter RM and Kunkel SL: Multiple roles for IL-12 in a model of
acute septic peritonitis. J Immunol. 162:5437–5443. 1999.PubMed/NCBI
|
|
36
|
Song GY, Chung CS, Chaudry IH and Ayala A:
What is the role of interleukin 10 in polymicrobial sepsis:
Anti-inflammatory agent or immunosuppressant? Surgery. 126:378–383.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nijsten MW, Hack CE, Helle M, ten Duis HJ,
Klasen HJ and Aarden LA: Interleukin-6 and its relation to the
humoral immune response and clinical parameters in burned patients.
Surgery. 109:761–767. 1991.PubMed/NCBI
|
|
38
|
Heinzel FP: The role of IFN-gamma in the
pathology of experimental endotoxemia. J Immunol. 145:2920–2924.
1990.PubMed/NCBI
|
|
39
|
Jaime-Figueroa S, De Vicente J, Hermann J,
Jahangir A, Jin S, Kuglstatter A, Lynch SM, Menke J, Niu L, Patel
V, et al: Discovery of a series of novel
5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase
inhibitors. Bioorg Med Chem Lett. 23:2522–2526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
O'Shea JJ, Pesu M, Borie DC and Changelian
PS: A new modality for immunosuppression: Targeting the JAK/STAT
pathway. Nat Rev Drug Discov. 3:555–564. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Olsen JV, Blagoev B, Gnad F, Macek B,
Kumar C, Mortensen P and Mann M: Global, in vivo, and site-specific
phosphorylation dynamics in signaling networks. Cell. 127:635–648.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Barahmand-Pour F, Meinke A, Groner B and
Decker T: Jak2-Stat5 interactions analyzed in yeast. J Biol Chem.
273:12567–12575. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gupta S, Yan H, Wong LH, Ralph S,
Krolewski J and Schindler C: The SH2 domains of Stat1 and Stat2
mediate multiple interactions in the transduction of IFN-alpha
signals. EMBO J. 15:1075–1084. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
O'Shea JJ, Holland SM and Staudt LM: JAKs
and STATs in immunity, immunodeficiency, and cancer. N Engl J Med.
368:161–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
O'Shea JJ, Schwartz DM, Villarino AV,
Gadina M, Mcinnes IB and Laurence A: The JAK-STAT pathway: Impact
on human disease and therapeutic intervention. Annu Rev Med.
66:311–328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Meier JA and Larner AC: Toward a new
STATe: The role of STATs in mitochondrial function. Semin Immunol.
26:20–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Leonard WJ and O'Shea JJ: Jaks and STATs:
Biological implications. Annu Rev Immunol. 16:293–322. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xiang Z, Zhao Y, Mitaksov V, Fremont DH,
Kasai Y, Molitoris A, Ries RE, Miner TL, McLellan MD, DiPersio JF,
et al: Identification of somatic JAK1 mutations in patients with
acute myeloid leukemia. Blood. 111:4809–4812. 2008. View Article : Google Scholar
|
|
50
|
Luo Q, Wang C, Jin G, Gu D, Wang N, Song
J, Jin H, Hu F, Zhang Y, Ge T, et al: LIFR functions as a
metastasis suppressor in hepatocellular carcinoma by negatively
regulating phosphoinositide 3-kinase/AKT pathway. Carcinogenesis.
36:1201–1212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li SJ, Sui MH, Sun ZX and Zhang WW: LncRNA
00152 promotes the development of hepatocellular carcinoma by
activating JAK2/STAT3 pathway. Eur Rev Med Pharmacol Sci.
23:1038–1046. 2019.PubMed/NCBI
|
|
52
|
Wu Y, Yuan T, Wang WW, Ge PL, Gao ZQ,
Zhang G, Tang Z, Dang XW, Zhao YF, Zhang JY and Jiang GZ: Long
noncoding RNA HOST2 promotes epithelial-mesenchymal transition,
proliferation, invasion and migration of hepatocellular carcinoma
cells by activating the JAK2-STAT3 signaling pathway. Cell Physiol
Biochem. 51:301–314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shu G, Zhao W, Yue L, Su H and Xiang M:
Antitumor immu-nostimulatory activity of polysaccharides from
Salvia chinensis Benth. J Ethnopharmacol. 168:237–247. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sun L, Feng L and Cui J: Increased
expression of claudin-17 promotes a malignant phenotype in
hepatocyte via Tyk2/Stat3 signaling and is associated with poor
prognosis in patients with hepatocellular carcinoma. Diagn Pathol.
13:722018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen G, Wang H, Xie S, Ma J and Wang G:
STAT1 negatively regulates hepatocellular carcinoma cell
proliferation. Oncol Rep. 29:2303–2310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu LY, Huang C, Li ZF, Wang AY, Hu XY, Ni
L, Yu L and Song TS: STAT1 and STAT2 participate in growth
inhibition of human hepatoma HepG2 cells induced by
phosphatidyletha-nolamine. Nan Fang Yi Ke Da Xue Xue Bao.
31:256–258. 2011.In Chinese. PubMed/NCBI
|
|
57
|
Zhang L, Xu K, Liu C and Chen J:
Meta-analysis reveals an association of signal transducer and
activator of transcription-4 polymorphism with hepatocellular
carcinoma risk. Hepatol Res. 47:303–311. 2017. View Article : Google Scholar
|
|
58
|
Tefferi A: JAK and MPL mutations in
myeloid malignancies. Leuk Lymphoma. 49:388–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Scott LM: The JAK2 exon 12 mutations: A
comprehensive review. Am J Hematol. 86:668–676. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Levine RL, Pardanani A, Tefferi A and
Gilliland DG: Role of JAK2 in the pathogenesis and therapy of
myeloproliferative disorders. Nat Rev Cancer. 7:673–683. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sakaguchi H, Okuno Y, Muramatsu H, Yoshida
K, Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba K, Tanaka H, et
al: Exome sequencing identifies secondary mutations of SETBP1 and
JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 45:937–941.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Villarino AV, Kanno Y, Ferdinand JR and
O'Shea JJ: Mechanisms of Jak/STAT signaling in immunity and
disease. J Immunol. 194:21–27. 2015. View Article : Google Scholar :
|
|
63
|
Manolio TA: Bringing genome-wide
association findings into clinical use. Nat Rev Genet. 14:549–558.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
O'Shea JJ, Lahesmaa R, Vahedi G, Laurence
A and Kanno Y: Genomic views of STAT function in CD4+ T helper cell
differentiation. Nat Rev Immunol. 11:239–250. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Vercelli D: Discovering susceptibility
genes for asthma and allergy. Nat Rev Immunol. 8:169–182. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Talati PG, Gu L, Ellsworth EM, Girondo MA,
Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD,
et al: Jak2-stat5a/b signaling induces epithelial-to-mesenchymal
transition and stem-like cell properties in prostate cancer. Am J
Pathol. 185:2505–2522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Loncle C, Bonjoch L, Folch-Puy E,
Lopez-Millan MB, Lac S, Molejon MI, Chuluyan E, Cordelier P, Dubus
P, Lomberk G, et al: IL-17 functions through the novel
REG3β-JAK2-STAT3 inflammatory pathway to promote the transition
from chronic pancreatitis to pancreatic cancer. Cancer Res.
75:4852–4862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Calvisi DF, Ladu S, Gorden A, Farina M,
Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous
activation of ras and Jak/stat pathways in human HCC.
Gastroenterology. 130:1117–1128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Spannbauer MM and Trautwein C: Frequent
in-frame somatic deletions activate gp130 in inflammatory
hepatocellular tumors. Hepatology. 49:1387–1389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
He G and Karin M: NF-kB and STAT3-key
players in liver inflammation and cancer. Cell Res. 21:159–168.
2011. View Article : Google Scholar
|
|
71
|
Liao Y, Cai B, Li Y and Wang L: P0360:
STAT6 rs3024974 might predict worse prognosis in hepatocellular
carcinoma patients. J Hepatol. 62(Suppl 2): S445–S446. 2015.
View Article : Google Scholar
|
|
72
|
Shi SY, Schroer SA, Luk CT, Kim MJ,
Dodington DW, Sivasubramaniyam T, Lin L, Cai EP, Lu SY, Wagner KU,
et al: Janus kinase 2 (JAK2) dissociates hepatosteatosis from
hepatocellular carcinoma in mice. J Biol Chem. 292:3789–3799. 2017.
View Article : Google Scholar : PubMed/NCBI
|
